Plaque Psoriasis Market Research Report: Information By Treatment (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies, and Others), By Route of Administration (Oral, and Injectable), By End Users (Hospitals, Homecare, Speciality Centres, and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Plaque Psoriasis Market Overview

Plaque Psoriasis Market Size was valued at USD 15.3 Billion in 2022. The plaque Psoriasis industry is projected to grow from USD 16.6 Billion in 2023 to USD 32.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.80% during the forecast period (2024 - 2032). Enhanced knowledge about Psoriasis, its symptoms, and treatment options among medical professionals and patients are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Plaque Psoriasis Market Trends

• Growing Patient Demand for Higher Living Standards is driving the market growth.

Market CAGR for plaque Psoriasis is being driven by the Growing Patient Demand for Higher Living Standards. Eighty to ninety percent of cases of total Psoriasis are caused by plaque Psoriasis, the most common type of Psoriasis. An autoimmune disease called plaque Psoriasis causes thick, angry skin patches. Usually, these plaques show up on the elbows, scalp, and knees. But they can also show up on other bodily parts. They itch, hurt, and have the potential to bleed. We still don't know the precise cause of plaque Psoriasis.

Additionally, patients look for therapies that enhance their general quality of life in addition to relieving symptoms. The market is moving toward more patient-centered and efficient treatments as a result of this demand. The landscape of treatment has changed with the advent of biologic medications and targeted therapies created especially to address the underlying causes of plaque Psoriasis. These treatments promote market growth and provide more effective outcomes. New and improved treatments for plaque Psoriasis are being discovered as a result of ongoing research and development efforts. Growth in the market is fueled by developments in systemic therapy, topical medications, and biologics, which increase treatment options.

Novel medications and treatment procedures are developed with the help of technological and scientific advancements in the pharmaceutical industry. More effective and focused treatments are produced as a result of these advancements. Pharmaceutical businesses spend a lot of money on research and development in an effort to find and commercialize novel therapies. These expenditures result in the creation of novel medications, increasing the range of treatment choices. Growth in the industry is mostly dependent on government programs and initiatives that support education, research, and access to therapies for long-term illnesses like plaque Psoriasis.

For instance, a positive opinion has been given to BIMZELX (bimekizumab), an investigational IL-17A and IL-17F inhibitor, by the Committee of Experts for Pharmaceutical Products for Human Use (CHMP) of the European Medicines Agency (EMA) for use in the management of moderate to severe plaque psoriasis in adults that are suitable candidates for comprehensive treatment. Thus, this results in driving the plaque Psoriasis market revenue.

Plaque Psoriasis Market Segment Insights

Plaque Psoriasis Treatment Insights

The plaque Psoriasis market segmentation, based on Treatment includes Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies, and Others. The biologic therapies segment dominated the market. This is a result of the fact that numerous major corporations have determined that launching new goods is a perfect way to expand their market share.

Plaque Psoriasis Route of Administration Insights

The plaque Psoriasis market segmentation, based on Route of Administration, includes Oral, and Injectable. The oral category generated the most income, because of the quick prescriptions. The market has grown significantly as a result of the major companies' quick research and development on these applications.

Plaque Psoriasis End Users Insights

The plaque Psoriasis market segmentation, based on End Users includes Hospitals, Homecare, Speciality Centres, and Others. The hospitals segment dominated the market. Because sophisticated medicines for severe cases of plaque Psoriasis require unique monitoring, infusion, or administration protocols, hospital administration is frequently required. Examples of this therapy include biologic medications and targeted immunomodulators.

Plaque Psoriasis Distribution Channel Insights

The plaque Psoriasis market segmentation, based on distribution channel, includes Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The retail pharmacy category generated the most income. The existence of numerous independent retail pharmacies throughout the world, particularly in emerging nations, is the cause of this dominance.

Figure1: Plaque Psoriasis Market, by Distribution channel, 2022&2032(USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Plaque Psoriasis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American plaque Psoriasis market area will dominate this market, because of the disease's rising prevalence. Additionally, throughout the projection period, the region's plaque Psoriasis market will profit from a strong medication pipeline. The Asia-Pacific market for plaque Psoriasis is anticipated to develop significantly because to the rise in research investment.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure2:  PLAQUE PSORIASIS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe plaque Psoriasis market has the second-largest portion of the market. European pharmaceutical businesses compete fiercely, which fosters innovation and the introduction of novel therapies into the market. Further, the German plaque Psoriasis market had the biggest market share, and the UK plaque Psoriasis market was the European market with the quickest rate of growth.

The Asia-Pacific Plaque Psoriasis Market is anticipated to expand between 2023 and 2032 at the quickest CAGR. This is because patients are seeking a better quality of life and are becoming more aware of the therapies available for plaque Psoriasis. Moreover, China’s plaque Psoriasis market had the biggest market share, and the Indian plaque Psoriasis market was the Asia-Pacific region's fastest-growing market.

Plaque Psoriasis Key Market Players& Competitive Insights

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the plaque Psoriasis market keep expanding. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure an increasingly cutthroat and dynamic market, plaque Psoriasis industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the plaque Psoriasis industry to help customers and expand the market segment. In recent years, the plaque Psoriasis industry has provided some of the biggest benefits to medicine. Major players in the plaque Psoriasis market, including Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany., and others, are engaging in research and development activities in an effort to boost market demand.

Pfizer Inc. is a pharmaceutical company with its main office located in New York City, USA. The world's largest over the counter (OTC) business with strong, recognizable brands was to be created by Pfizer and GlaxoSmithKline plc through the closure of their joint venture, which was announced in 2019. The venture combined the parties' respective consumer healthcare businesses. During the same year, Pfizer also revealed its intention to merge Upjohn, its off-patent branded and generic established medicines business, with Mylan, a multinational pharmaceutical company with a broad portfolio and presence, to form a new  health champion that is well-positioned to meet the world's medical needs.

GlaxoSmithKline plc* is based in Brentford, London, and is a British enterprise. With combined revenues of over £9.8 billion ($12.7 billion), GSK and Pfizer Inc. announced in 2019 that they had reached an agreement to merge their consumer health businesses into a new, industry-leading joint venture. GSK also declared in the same year that it would concentrate on four therapeutic areas: immunology, cancer, HIV, and infectious illnesses.

Key Companies in the plaque Psoriasis market include

• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Novartis AG (Switzerland)


• Mylan N.V. (US)


• Teva Pharmaceutical Industries Ltd.(Israel)


• Sanofi (France)


• Boehringer Ingelheim International GmbH. (Germany)


• AstraZeneca (UK)


• Johnson & Johnson Private Limited (US)


• Bayer AG (Germany)


• Merck & Co., Inc. (US)


• Hoffmann-La Roche Ltd. (Switzerland)


• Bristol-Myers Squibb Company (US)


• Cadila Pharmaceuticals (India)


• Eli Lilly and Company (US)


• LEO Pharma A/S (Denmark)


• Cipla Inc. (US)


• Aurobindo Pharma (India)


• Lupin (India)


• Sumitomo Corporation (Japan)

Plaque Psoriasis Industry Developments

May 2020: Novartis declared that the European Commission had approved Zolgensma, a gene therapy product, to treat spinal muscular atrophy (SMA) in individuals up to 21 kg in weight.

August 2021: Novartis declared that the US FDA had approved Leqvio, a medication, to treat mixed dyslipidemia (MDL) or familial hypercholesterolemia (FH).

November 2019: Bristol-Myers Squibb announced that it had successfully acquired Celgene Corporation, a biopharmaceutical business that specializes in creating therapies for inflammatory illnesses and cancer.

Plaque Psoriasis Market Segmentation

Plaque Psoriasis Treatment Outlook

• Topical Therapy


• Phototherapy


• Systemic Agents


• Biologic Therapies


• Others

Plaque Psoriasis Route of Administration Outlook

• Oral


• Injectable

Plaque Psoriasis End Users Outlook

• Hospitals


• homecare


• Speciality Centres


• Others

Plaque Psoriasis Distribution Channel Outlook

• Hospital Pharmacy


• Online Pharmacy


• Retail Pharmacy

Plaque Psoriasis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America